BBLG vs BCAB

Bone Biologics Corp vs BioAtla, Inc. — Valuation Comparison 2026

BBLG

Biotechnology
Bone Biologics Corp
Quality
3.7
out of 10
Value Trap
12
SAFE
Price
$1.30
Last close
Models
7/13
Active
VS

BCAB

Biotechnology
BioAtla, Inc.
Quality
3.4
out of 10
Value Trap
30
LOW
Price
$4.05
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType BBLG Fair ValueBBLG Upside BCAB Fair ValueBCAB Upside
Bayesian DCF Intrinsic $1.73 +32.6% $1.80 -55.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.30 -76.9% $0.19 -95.5%
Dynamic NAV Asset-Based $7.68 +488.3% $22.05 +444.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BBLG vs BCAB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BBLG vs BCAB — Which Stock Is More Undervalued?

BBLG scores higher with a 3.7/10 quality rating vs BCAB's 3.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Bone Biologics Corp (BBLG) and BioAtla, Inc. (BCAB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BBLG currently trades at $1.30 with a QOC of 3.7/10, while BCAB trades at $4.05 with a QOC of 3.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).